News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
211,733 Results
Type
Article (7168)
Company Profile (38)
Press Release (204527)
Multimedia
Podcasts (24)
Webinars (5)
Section
Business (55524)
Career Advice (173)
Deals (10642)
Drug Delivery (45)
Drug Development (12391)
Employer Resources (35)
FDA (5796)
Job Trends (5354)
News (86931)
Policy (8651)
Tag
Academia (704)
Accelerated approval (1)
Adcomms (1)
Allergies (32)
Alliances (15274)
ALS (14)
Alzheimer's disease (333)
Antibody-drug conjugate (ADC) (27)
Approvals (5860)
Artificial intelligence (159)
Autoimmune disease (5)
Automation (5)
Bankruptcy (67)
Best Places to Work (4869)
BIOSECURE Act (4)
Biosimilars (55)
Biotechnology (18)
Bladder cancer (28)
Brain cancer (4)
Breast cancer (103)
Cancer (598)
Cardiovascular disease (68)
Career advice (166)
Career pathing (2)
CAR-T (21)
Cell therapy (86)
Cervical cancer (7)
Clinical research (10635)
Collaboration (298)
Compensation (25)
Complete response letters (2)
COVID-19 (734)
CRISPR (11)
C-suite (110)
Cystic fibrosis (19)
Data (701)
Decentralized trials (1)
Denatured (10)
Depression (14)
Diabetes (92)
Diagnostics (3227)
Digital health (11)
Diversity (3)
Diversity, equity & inclusion (11)
Drug discovery (36)
Drug pricing (47)
Drug shortages (6)
Duchenne muscular dystrophy (35)
Earnings (18101)
Editorial (17)
Employer branding (1)
Employer resources (31)
Events (48354)
Executive appointments (312)
FDA (6343)
Frontotemporal dementia (4)
Funding (279)
Gene editing (24)
Generative AI (17)
Gene therapy (73)
GLP-1 (184)
Government (1359)
Grass and pollen (2)
Guidances (69)
Healthcare (8627)
Huntington's disease (2)
IgA nephropathy (14)
Immunology and inflammation (19)
Indications (13)
Infectious disease (788)
Inflammatory bowel disease (42)
Inflation Reduction Act (5)
Influenza (16)
Intellectual property (20)
Interviews (15)
IPO (4305)
IRA (16)
Job creations (713)
Job search strategy (154)
Kidney cancer (1)
Labor market (6)
Layoffs (78)
Legal (1651)
Liver cancer (16)
Lung cancer (80)
Lymphoma (41)
Machine learning (3)
Management (14)
Manufacturing (82)
MASH (24)
Medical device (6154)
Medtech (6154)
Mergers & acquisitions (6607)
Metabolic disorders (244)
Multiple sclerosis (37)
NASH (5)
Neurodegenerative disease (17)
Neuropsychiatric disorders (8)
Neuroscience (468)
NextGen: Class of 2025 (2903)
Non-profit (1544)
Now hiring (3)
Obesity (131)
Opinion (66)
Ovarian cancer (19)
Pain (21)
Pancreatic cancer (12)
Parkinson's disease (22)
Partnered (7)
Patents (40)
Patient recruitment (36)
Peanut (19)
People (18623)
Pharmaceutical (12)
Pharmacy benefit managers (9)
Phase I (2248)
Phase II (3741)
Phase III (5074)
Pipeline (446)
Policy (48)
Postmarket research (735)
Preclinical (729)
Press Release (10)
Prostate cancer (37)
Psychedelics (5)
Radiopharmaceuticals (75)
Rare diseases (111)
Real estate (1406)
Recruiting (11)
Regulatory (6362)
Reports (16)
Research institute (627)
Resumes & cover letters (13)
Rett syndrome (3)
RNA editing (1)
RSV (17)
Schizophrenia (20)
Series A (44)
Series B (41)
Service/supplier (3)
Sickle cell disease (25)
Special edition (6)
Spinal muscular atrophy (35)
Sponsored (6)
Startups (1231)
Stomach cancer (2)
Supply chain (24)
Tariffs (14)
The Weekly (14)
Vaccines (164)
Venture capitalists (18)
Weight loss (65)
Women's health (22)
Worklife (2)
Date
Today (60)
Last 7 days (309)
Last 30 days (958)
Last 365 days (11453)
2025 (4431)
2024 (11925)
2023 (13066)
2022 (20210)
2021 (21556)
2020 (20910)
2019 (17773)
2018 (13129)
2017 (8988)
2016 (9589)
2015 (11009)
2014 (8133)
2013 (6711)
2012 (7000)
2011 (6967)
2010 (5591)
Location
Africa (230)
Alabama (14)
Alaska (1)
Arizona (71)
Arkansas (6)
Asia (11002)
Australia (1470)
California (1872)
Canada (654)
China (167)
Colorado (124)
Connecticut (82)
Delaware (54)
Europe (26674)
Florida (331)
Georgia (94)
Hawaii (1)
Idaho (18)
Illinois (232)
India (18)
Indiana (142)
Iowa (1)
Japan (82)
Kansas (24)
Kentucky (14)
Louisiana (8)
Maine (26)
Maryland (249)
Massachusetts (1490)
Michigan (95)
Minnesota (139)
Mississippi (2)
Missouri (55)
Montana (5)
Nebraska (13)
Nevada (21)
New Hampshire (25)
New Jersey (727)
New Mexico (7)
New York (637)
North Carolina (416)
North Dakota (1)
Northern California (843)
Ohio (68)
Oklahoma (6)
Oregon (11)
Pennsylvania (550)
Puerto Rico (3)
Rhode Island (8)
South America (310)
South Carolina (11)
Southern California (697)
Tennessee (73)
Texas (267)
United States (8102)
Utah (107)
Virginia (49)
Washington D.C. (25)
Washington State (151)
West Virginia (3)
Wisconsin (26)
211,733 Results for "viiv healthcare".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground
Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.
October 17, 2024
·
2 min read
·
Tristan Manalac
Press Releases
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
March 27, 2025
·
6 min read
Press Releases
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
March 13, 2025
·
10 min read
Press Releases
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
February 14, 2025
·
5 min read
Business
Exavir Therapeutics Announces Entry Into a Litigation Settlement and License Agreement For Ultra-Long-Acting HIV Compounds With ViiV Healthcare
Today, Exavir Therapeutics announced that the company has entered into a settlement and license agreement with ViiV Healthcare for ultra-long-acting HIV compounds.
May 22, 2024
·
1 min read
FDA
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV.
April 8, 2024
·
10 min read
WHO Warns of Growing Resistance in Individuals to GSK, ViiV’s HIV Drug Tivicay
The World Health Organization has detected signals of growing HIV resistance to GSK and ViiV Healthcare’s Tivicay, which it says must be minimized as part of the broader global response to antimicrobial resistance.
March 6, 2024
·
2 min read
·
Tristan Manalac
Bio NC
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine jointly announced the launch of The Dr. Dawn K. Smith HIV Prevention Clinical Fellowship.
March 5, 2024
·
6 min read
Press Releases
ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow
November 8, 2024
·
18 min read
1 of 21,174
Next
